Statin treatment for unruptured intracranial aneurysms study: a study protocol for a double-blind, placebo-controlled trial

Wenqiang Li, Yisen Zhang, Zhongbin Tian, Wei Zhu, Jian Liu, Ying Zhang, Xinjian Yang, De-Cai Tian, Wenqiang Li, Yisen Zhang, Zhongbin Tian, Wei Zhu, Jian Liu, Ying Zhang, Xinjian Yang, De-Cai Tian

Abstract

Background and purpose: A large proportion of patients with unruptured intracranial aneurysm (IA) are not suitable for surgical clipping and endovascular treatment. For these patients, anti-inflammatory medications are worth exploring due to inflammation of aneurysmal wall being a major factor in higher risk of rupture. Statin has been proven to reduce inflammation of atherosclerosis and maybe a suitable candidate. This study aimed to evaluate whether atorvastatin will reduce inflammatory of the aneurysm wall measured by the signal index of aneurysm wall enhancement.

Methods and analysis: The Statin Treatment for UnruptureD Intracranial anEurysms Study is a single-centre, phase 2, randomised, controlled, double-blind clinical trial. 60 patients with unruptured IAs with aneurysm wall enhancement will be enrolled in Beijing Tiantan Hospital. The patients will be randomised to receive atorvastatin 20 mg or placebo orally per day for 12 months. The primary outcome will be the change in aneurysm wall enhancement measured by the signal index during the 12 months treatment with atorvastatin. The secondary study outcomes will be the change in aneurysm wall enhancement measured by the signal index at 3 months, the changes in aneurysmal morphology and inflammation-related factors (C reactive protein, tumour necrosis factor-α, interleukin-1β and interleukin-6) at 3 and 12 months. This study is the first to explore the role of atorvastatin in reducing inflammation in unruptured IA, which could lay the groundwork for future phase III trial.

Ethics and dissemination: Beijing Tiantan Hospital's Ethics committee approved the research and written informed consents would be obtained from all participant or representative included in this study.

Trial registration number: NCT04149483.

Keywords: MRI; aneurysm; inflammation; vessel wall.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. Lancet 2017;389:655–66. 10.1016/S0140-6736(16)30668-7
    1. Nieuwkamp DJ, Setz LE, Algra A, et al. . Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol 2009;8:635–42. 10.1016/S1474-4422(09)70126-7
    1. Stegmayr B, Eriksson M, Asplund K. Declining mortality from subarachnoid hemorrhage: changes in incidence and case fatality from 1985 through 2000. Stroke 2004;35:2059–63. 10.1161/01.STR.0000138451.07853.b6
    1. Brown RD, Broderick JP. Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening. Lancet Neurol 2014;13:393–404. 10.1016/S1474-4422(14)70015-8
    1. The UCAS Japan Investigators The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med Overseas Ed 2012;366:2474–82. 10.1056/NEJMoa1113260
    1. Frösen J, Tulamo R, Paetau A, et al. . Saccular intracranial aneurysm: pathology and mechanisms. Acta Neuropathol 2012;123:773–86. 10.1007/s00401-011-0939-3
    1. Jamous MA, Nagahiro S, Kitazato KT, et al. . Endothelial injury and inflammatory response induced by hemodynamic changes preceding intracranial aneurysm formation: experimental study in rats. J Neurosurg 2007;107:405–11. 10.3171/JNS-07/08/0405
    1. Meng H, Tutino VM, Xiang J, et al. . High WSS or low WSS? complex interactions of hemodynamics with intracranial aneurysm initiation, growth, and rupture: toward a unifying hypothesis. AJNR Am J Neuroradiol 2014;35:1254–62. 10.3174/ajnr.A3558
    1. Frösen J. Smooth muscle cells and the formation, degeneration, and rupture of saccular intracranial aneurysm wall--a review of current pathophysiological knowledge. Transl Stroke Res 2014;5:347–56. 10.1007/s12975-014-0340-3
    1. Etminan N, Rinkel GJ. Unruptured intracranial aneurysms: development, rupture and preventive management. Nat Rev Neurol 2016;12:699–713. 10.1038/nrneurol.2016.150
    1. Shimonaga K, Matsushige T, Ishii D, et al. . Clinicopathological insights from vessel wall imaging of unruptured intracranial aneurysms. Stroke 2018;49:2516–9. 10.1161/STROKEAHA.118.021819
    1. Lehman VT, Brinjikji W, Mossa-Basha M, et al. . Conventional and high-resolution vessel wall MRI of intracranial aneurysms: current concepts and new horizons. J Neurosurg 2018;128:969–81. 10.3171/2016.12.JNS162262
    1. Samaniego EA, Roa JA, Hasan D. Vessel wall imaging in intracranial aneurysms. J Neurointerv Surg 2019;11:1105–12. 10.1136/neurintsurg-2019-014938
    1. Bellosta S, Ferri N, Bernini F, et al. . Non-lipid-related effects of statins. Ann Med 2000;32:164–76. 10.3109/07853890008998823
    1. Jiang R, Zhao S, Wang R, et al. . Safety and efficacy of atorvastatin for chronic subdural hematoma in Chinese patients: a randomized ClinicalTrial. JAMA Neurol 2018;75:1338–46. 10.1001/jamaneurol.2018.2030
    1. Potey C, Ouk T, Petrault O, et al. . Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia. Br J Pharmacol 2015;172:5188–98. 10.1111/bph.13285
    1. Aikawa M, Rabkin E, Sugiyama S, et al. . An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276–83. 10.1161/01.CIR.103.2.276
    1. Aoki T, Kataoka H, Ishibashi R, et al. . Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. Stroke 2008;39:1276–85. 10.1161/STROKEAHA.107.503086
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. . Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586
    1. Omodaka S, Endo H, Niizuma K, et al. . Circumferential wall enhancement on magnetic resonance imaging is useful to identify rupture site in patients with multiple cerebral aneurysms. Neurosurgery 2018;82:638–44. 10.1093/neuros/nyx267
    1. Omodaka S, Endo H, Niizuma K, et al. . Quantitative assessment of circumferential enhancement along the wall of cerebral aneurysms using MR imaging. AJNR Am J Neuroradiol 2016;37:1262–6. 10.3174/ajnr.A4722
    1. Tian B, Toossi S, Eisenmenger L, et al. . Visualizing wall enhancement over time in unruptured intracranial aneurysms using 3D vessel wall imaging. J Magn Reson Imaging 2019;50:193–200. 10.1002/jmri.26553
    1. Tada Y, Kitazato KT, Yagi K, et al. . Statins promote the growth of experimentally induced cerebral aneurysms in estrogen-deficient rats. Stroke 2011;42:2286–93. 10.1161/STROKEAHA.110.608034
    1. Can A, Castro VM, Dligach D, et al. . Lipid-Lowering agents and high HDL (high-density lipoprotein) are inversely associated with intracranial aneurysm rupture. Stroke 2018;49:1148–54. 10.1161/STROKEAHA.117.019972
    1. Yoshimura Y, Murakami Y, Saitoh M, et al. . Statin use and risk of cerebral aneurysm rupture: a hospital-based case-control study in Japan. J Stroke Cerebrovasc Dis 2014;23:343–8. 10.1016/j.jstrokecerebrovasdis.2013.04.022
    1. Marbacher S, Schläppi J-A, Fung C, et al. . Do statins reduce the risk of aneurysm development? A case-control study. J Neurosurg 2012;116:638–42. 10.3171/2011.10.JNS11153
    1. Mancini GBJ, Baker S, Bergeron J, et al. . Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus Working group update (2016). Can J Cardiol 2016;32:S35–65. 10.1016/j.cjca.2016.01.003
    1. Stroes ES, Thompson PD, Corsini A, et al. . Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J 2015;36:1012–22. 10.1093/eurheartj/ehv043
    1. Kajimoto K, Miyauchi K, Kasai T, et al. . Short-Term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009;206:505–11. 10.1016/j.atherosclerosis.2009.03.028
    1. Komukai K, Kubo T, Kitabata H, et al. . Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol 2014;64:2207–17. 10.1016/j.jacc.2014.08.045

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever